|
Guzman-Laiz R, Iniesta-Navalon C, Rios-Saorin M, Anez-Castano R, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Utility of tolerance assays for real-time management of infliximab infusion reactions. Rev Esp Enferm Dig. 2026 Jan 22. doi: 10.17235/reed.2026.11049/2024. Online ahead of print. PubMed PMID: 41569131.
AÑO: 2026; IF: 4.0
|
41569131
|
Guzman-Laiz R, Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Garcia-Masegosa I, Anez-Castano R, Urbieta-Sanz E. Immunogenicity phenotypes and reversal of pharmacokinetic impact in anti-TNF-treated immune-mediated diseases: a real-world study. Int J Clin Pharm. 2026 Feb;48(1):246-256. doi: 10.1007/s11096-025-02043-6. Epub 2025 Nov 15. PubMed PMID: 41240271.
AÑO: 2026; IF: 3.2
|
|
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, Urbieta-Sanz E. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients. Gastroenterol Hepatol. 2025 Jun-Jul;48(6):502277. doi: 10.1016/j.gastrohep.2024.502277. Epub 2024 Oct 21. English, Spanish. PubMed PMID: 39442691.
AÑO: 2025; IF: 1.9
|
|
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Gascon-Canovas JJ, Gonzalez-Molina MR, Prado IN, Gomez-Espin R, Urbieta-Sanz E. STRATIfy-PK SCORE: A predictive tool for identifying pharmacokinetic failure risk in anti-TNF-treated patient. Br J Clin Pharmacol. 2025 Nov 21. doi: 10.1002/bcp.70346. Online ahead of print. PubMed PMID: 41268891.
AÑO: 2025; IF: 3.0
|
|
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta-Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2025 Apr;117(4):205-212. doi: 10.17235/reed.2024.10521/2024. PubMed PMID: 39629805.
AÑO: 2025; IF: 4.0
|